Navigation Links
AtriCure Announces Web Cast and Conference Call of Third Quarter 2007 Financial Results
Date:10/22/2007

WEST CHESTER, Ohio, Oct. 22 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative cardiac surgical devices, will release its financial results for the quarter ended September 30, 2007 on Tuesday, November 6, 2007.

AtriCure will host a conference call at 10:00 am ET on Tuesday, November 6, 2007 to discuss third quarter 2007 results. A live web cast of the conference call will be available online from the investor relations page of AtriCure's corporate web site at http://www.atricure.com.

Pre-registration is available for this call at the following URL: https://www.theconferencingservice.com/prereg/key.process?key=PWTAHHJ3Q

Pre-registering is not mandatory but is recommended as it will provide you immediate entry into the call and will facilitate the timely start of the conference. Pre-registration only takes a few moments and you may pre-register at any time, including up to and after the call start time. Alternatively, if you prefer being placed into the call by an operator, please call (888) 713-4218 for domestic callers and (617) 213-4870 for international callers at least 15 minutes prior to the call start time and use reservation number 91207687.

The web cast will remain available on AtriCure's web site through December 6, 2007. A telephonic replay of the call will also be available until December 6, 2007. The replay dial-in numbers are (888) 286-8010 for domestic callers and (617) 801-6888 for international callers. Please use reservation code 85213467.

About AtriCure, Inc.

AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative cardiac surgical devices designed to create precise lesions, or scars, in cardiac, or heart, tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure Isolator(R) bipolar ablation clamps as a treatment alternative during open-heart surgical procedures to create lesions in cardiac tissue to block the abnormal electrical impulses that cause atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart. Additionally, leading cardiothoracic surgeons have described the AtriCure Isolator(R) clamps as a promising treatment alternative for patients who may be candidates for sole-therapy minimally invasive procedures. AF affects more than 2.5 million Americans and predisposes them to a five-fold increased risk of stroke.

The FDA has cleared the AtriCure Isolator(R) bipolar ablation system, including the new Isolator Synergy(TM) ablation clamps, for the ablation, or destruction, of soft tissues in general and cardiac related surgical procedures, but to date has not cleared or approved the system for the treatment of AF. The FDA has cleared the AtriCure multifunctional bipolar Pen for the ablation of cardiac tissue and for temporary pacing, sensing, stimulating and recording during the evaluation of cardiac arrhythmias, but the multifunctional bipolar Pen has not been approved for the treatment of AF.

Contact:

AtriCure, Inc.

Julie A. Piton

Vice President and Chief Financial Officer

(513) 755-4561

jpiton@atricure.com


'/>"/>
SOURCE AtriCure, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Suffern, NY (PRWEB) , ... March 28, 2017 ... ... and process management software and services, is proud to announce it has joined ... respected professional association representing the interests of chronically ill, disabled, and dying Americans ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... today that the University of Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding ... Pennsylvania. , The program, developed in association with efforts by the American College ...
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, qualification, and the ... results and maintaining GMP and USP compliance. In a new webinar from METTLER ... requirements " these requirements are explained. The challenge is to determine how ...
(Date:3/28/2017)... ... 28, 2017 , ... With less than 10,000 dermatologists in the United States ... be limited while the desire to conquer breakouts and eliminate skincare stress is widespread. ... customer online, today released its inaugural survey on the State of Acne in America. ...
(Date:3/28/2017)... ... March 28, 2017 , ... Columbus OH. Dr. Justin Harper, Founder of ... medical professionals in the country to sit on the 2017 National Advisory Board for ... 2 years Dr. Harper helped propel the clinic from a small start-up to number ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... and TORONTO , March ... leading full service medical device development firm, ... the visionary Toronto -based medical device ... will better serve medtech companies throughout North ... resources and experienced medical device talent spanning the design, ...
(Date:3/28/2017)... and TEL AVIV, Israel , March ... subsidiary in Israel . This new business entity, ... be mostly dedicated to research and development of novel assays complementing ... will also, when relevant, locally support commercialization and sales development of ... This ...
(Date:3/28/2017)... , March 28, 2017 RXi Pharmaceuticals ... innovative therapeutics that address significant unmet medical needs, ... from the Japan Patent Office (JPO) for the ... growth factor (CTGF) for the treatment or prevention ... skin fibrosis and proliferative retinopathy (Japanese Patent #: ...
Breaking Medicine Technology: